A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies

Trial Profile

A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Pembrolizumab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-013
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 11 Dec 2017 According to a Merck media release, data from this trial was presented at the 59th American Society of Hematology (ASH) Annual Meeting (2017).
    • 11 Dec 2017 The FDA granted Priority Review status with a PDUFA (target action) date of 3 Apr 2018, according to a Merck media release.
    • 11 Dec 2017 Based on data from KEYNOTE-170 and the phase Ib KEYNOTE-013 trial, the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal B-cell lymphoma, or who have relapsed after two or more prior lines of therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top